T-cell receptor-peptide-major histocompatibility complex class II (TCR-pMHCII)

The T-cell receptor (TCR) recognizing a helper epitope presented by the major histocompatibility complex class II (MHC II) is a fundamental molecular assembly in the adaptive immune system (Janeway's Immunobiology, 2017). This complex facilitates the recognition of exogenous antigens by CD4+ T helper cells, which subsequently orchestrate the immune response through cytokine secretion and B-cell activation (PubMed PMID: 25459012). In a therapeutic context, this interaction is targeted to either enhance immune responses against cancer and infections or to suppress unwanted responses in autoimmune diseases and organ transplantation (Nature Reviews Drug Discovery, 2018). Modern immunotherapies, such as TCR-engineered T-cell (TCR-T) therapies, specifically design TCRs to bind neoantigens or tumor-associated antigens presented on MHC II molecules (ClinicalTrials.gov NCT02111811). Additionally, drugs like calcineurin inhibitors and co-stimulation blockers modulate the signaling pathways initiated by this complex to prevent graft rejection (StatPearls, 2023). Understanding the specificity and affinity of the TCR-pMHCII interaction is crucial for developing precision medicines that can selectively modulate the immune system without causing systemic toxicity (Frontiers in Immunology, 2021).

Other names

TCR-MHC II complexCD4+ T-cell receptor complexMHC class II-restricted T-cell receptorAntigen-specific TCR-MHC II complexT-cell receptor-helper epitope-MHC II complex

T-cell receptor-mediated signaling, Antigen-specific T-cell redirection, Competitive inhibition of co-stimulation, Calcineurin inhibition, LAG-3 blockade